In 2017, Sail et al. (2017) identified the first small molecules that exhibit anti-TLS activity in human cancer cells through disruption of the protein-protein interactions between the C-terminal domain of REV1 and the REV1-interacting region. This evidence concerns the gene REV1 and cancer.